Hepatitis C and insulin resistance: Steatosis, fibrosis and nonresponse;Hepatitis C y resistencia a la insulina: Esteatosis, fibrosis y no respuesta

Revista Espanola de Enfermedades Digestivas

Volumn 98, Issue 8, 2006, Pages 605-615

  Romero Gomez M ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Fibrosis; Hepatitis C; Insulin resistance; Steatosis

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIBAVIRIN; TUMOR NECROSIS FACTOR;

BODY MASS; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; FIBROSIS; GENOTYPE; HEPATITIS C; HUMAN; HYPERLEPTINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MIXED INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STEATOSIS; FATTY LIVER; LIVER CIRRHOSIS; PATHOPHYSIOLOGY;

DISEASE PROGRESSION; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS;

EID: 37149056290     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082006000800006     Document Type: Review

References (41)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
2. Kruszynska YT, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology 1991; 14: 103-11.
3. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004; 41: 132-8.
4. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
5. Yazicioglu G, Isitan F, Altunbas H, et al. Insulin resistance in chronic hepatitis C. Int J Clin Pract 2004; 58: 1020-2.
6. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508.
7. Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2003; 18: 1358-63.
8. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005; 100: 48-55.
9. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
10. Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. a case-control study. Am J Gastroenterol 2003; 98: 438-41.
11. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-9.
12. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
13. Simo R, Hernández C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000.
14. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-6.
15. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol 2003; 158: 1154-60.
16. Romero Gómez M, Fernández-Rodríguez C, Diago M, et al. La curación de la hepatitis C reduce el riesgo de desarrollo de hiperglucemia y diabetes mellitus tipo 2. Gastroenterol Hepatol 2006; (en prensa).
17. Cammà C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in non-diabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43: 64-71.
18. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T; LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-55.
19. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
20. Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39: 1239-47.
21. Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6: 22-9.
22. Romero-Gómez M, Castellano-Megias VM, Grande L, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003; 98: 1135-41.
23. Otte C, Otte JM, Strodthoff D, et al. Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes 2004; 112: 10-7.
24. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in dipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166: 1655-69.
25. Sung CK, She H, Xiong S, Tsukamoto H. Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2004; 286: G722-9.
26. Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-42.
27. Burgess HA, Daugherty LE, Thatcher TH, et al. PPAR gamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1146-53.
28. Taiwo BO. Insulin resistance, HIV infection, and anti-HIV therapies. AIDS Read 2005; 15: 171-6, 179-80 (review).
29. Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005; 5: 255-62.
30. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naïve patients coinfected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect 2005; 50: 331-7.
31. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 245-50.
32. Romero Gómez M, Solà R, Tural C, et al. La resistencia a la insulina disminuye la respuesta sostenida a interferón pegilado más ribavirina en pacientes coinfectados VIH/VHC. Gastroenterol Hepatol 2006 (en prensa).
33. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641-7.
34. Imano E, Kanda T, Ishigami Y, et al. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 1998; 28: 189-93.
35. Ito Y, Takeda N, Ishimori M, Akai A, Miura K, Yasuda K. Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J Hepatol 1999; 31: 215-20.
36. Tai TY, Lu JY, Chen CL, et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178: 457-65.
37. Romero-Gómez M, González-Escribano MF, Torres B, et al. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Am J Gastroenterol 2003; 98: 1621-6.
38. Romero-Gómez M, Viloria MM, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
39. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-15.
40. Grace MJ, Cutler D. Pegylating IFNs at His-34 improves the in vitro anti-viral activity through the JAK/STAT pathway. Antiviral Chem Chem 2004; 15: 287-97.
41. Sanyal AJ, Chand N, Comar K, Mirshahi F. Hyperinsulinemia block the inhibition of HCV replication by interferon: A potential mechanism for failure of interferon therapy in subjects with HCV and NASH. Hepatology 2004; 40: 179A.